StockMacro
Menu

John Maraganore

Insider (Form 4 reporting owner): Director CIK 1180432Name as filed: MARAGANORE JOHNIts filings on EDGARAll insiders

Measures activity, not value. Not investment advice.

Since 19 Jan 2016, sold $80.5M in 17 sales and bought $249K in 1 open-market purchase across 3 companies.

Companies

Role on the latest Form 4 for each; open-market trades counted
CompanyRoleTrades fromtoPurchasesSales
Alnylam Pharmaceuticals ALNYChief Executive Officer19 Jan 201612 Nov 2021–16$78.5M
Agios Pharmaceuticals AGIODirector11 Sep 201812 Sep 2018–1$2.0M
Rapport Therapeutics RAPPDirector22 Oct 202622 Oct 20261$249K–

What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.

Median return minus the sector fund, in percentage points; "too few trades" under 5
Open-market tradesAfter 3 monthsAfter 6 monthsAfter 12 months
After purchasesno trade old enoughno trade old enoughno trade old enough
After sales-17.6 pts16 trades, 0.00% above the sector-29.6 pts16 trades, 0.00% above the sector+9.4 pts16 trades, 94% above the sector

For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.

By year

Counted open-market trades, by trade date
YearPurchasesBoughtSalesSoldNet
20261$249K––$249K
2021––4$22.1M-$22.1M
2020––4$18.6M-$18.6M
2019––2$7.4M-$7.4M
2018––2$7.3M-$7.3M
2017––2$19.0M-$19.0M
2016––3$6.1M-$6.1M

Every trade

19, newest first; open-market purchases and sales only
Trade dateCompanySideSharesPriceValuePlanned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. Filing
22 Oct 2026Rapport Therapeutics RAPPBuy9,411$26.45$249KNoForm 4filed 22 Oct 2026
12 Nov 2021Alnylam Pharmaceuticals ALNYSellafter exercising options33,978$171.52$5.8MNot statedForm 4filed 12 Nov 2021
13 Aug 2021Alnylam Pharmaceuticals ALNYSellafter exercising options33,979$199.78$6.8MNot statedForm 4filed 16 Aug 2021
13 May 2021Alnylam Pharmaceuticals ALNYSellafter exercising options33,979$130.78$4.4MNot statedForm 4filed 17 May 2021
25 Feb 2021Alnylam Pharmaceuticals ALNYSellafter exercising options33,979$147.31$5.0MNot statedForm 4filed 26 Feb 2021
19 Nov 2020Alnylam Pharmaceuticals ALNYSellafter exercising options34,765$124.23$4.3MNot statedForm 4filed 20 Nov 2020
20 Aug 2020Alnylam Pharmaceuticals ALNYSellafter exercising options34,765$136.13$4.7MNot statedForm 4filed 21 Aug 2020
20 May 2020Alnylam Pharmaceuticals ALNYSellafter exercising options34,765$143.22$5.0MNot statedForm 4filed 22 May 2020
20 Feb 2020Alnylam Pharmaceuticals ALNYSellafter exercising options34,765$131.85$4.6MNot statedForm 4filed 21 Feb 2020
14 Oct 2019Alnylam Pharmaceuticals ALNYSellafter exercising options49,456$79.45$3.9MNot statedForm 4filed 16 Oct 2019
15 May 2019Alnylam Pharmaceuticals ALNYSellafter exercising options49,457$70.00$3.5MNot statedForm 4filed 17 May 2019
12 Sep 2018Agios Pharmaceuticals AGIOSellamended filing (4/A), not counted again0Not filedNot filedNot statedForm 4/Afiled 6 Nov 2018
11 Sep 2018Agios Pharmaceuticals AGIOSell27,717$72.23$2.0MNot statedForm 4filed 13 Sep 2018
25 Jul 2018Alnylam Pharmaceuticals ALNYSellafter exercising options50,000$105.39$5.3MNot statedForm 4filed 27 Jul 2018
22 Nov 2017Alnylam Pharmaceuticals ALNYSellafter exercising options73,415$130.90$9.6MNot statedForm 4filed 24 Nov 2017
15 Nov 2017Alnylam Pharmaceuticals ALNYSellafter exercising options74,000$126.86$9.4MNot statedForm 4filed 17 Nov 2017
19 Jul 2016Alnylam Pharmaceuticals ALNYSellafter exercising options30,151$64.70$2.0MNot statedForm 4filed 21 Jul 2016
19 Apr 2016Alnylam Pharmaceuticals ALNYSellafter exercising options30,151$67.46$2.0MNot statedForm 4filed 21 Apr 2016
19 Jan 2016Alnylam Pharmaceuticals ALNYSellafter exercising options30,152$71.78$2.2MNot statedForm 4filed 21 Jan 2016

From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.